Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 Read more about Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Supernus Provides Regulatory Update for SPN-830 Read more about Supernus Provides Regulatory Update for SPN-830
Supernus to Participate in Two Upcoming Investor Conferences Read more about Supernus to Participate in Two Upcoming Investor Conferences
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference Read more about Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results Read more about Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024 Read more about Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent Read more about Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
Supernus Announces Third Quarter 2023 Financial Results Read more about Supernus Announces Third Quarter 2023 Financial Results
Supernus to Participate in the Jefferies London Healthcare Conference Read more about Supernus to Participate in the Jefferies London Healthcare Conference
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA Read more about Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA